**Core Concept**
C-MYC translocation involves the t(8;14) chromosomal abnormality, leading to the juxtaposition of the C-MYC gene with the immunoglobulin heavy chain gene. This results in the overexpression of the C-MYC protein, which is a transcription factor that regulates cell proliferation and apoptosis.

**Why the Correct Answer is Right**
The C-MYC translocation is a hallmark of Burkitt lymphoma, a type of B-cell non-Hodgkin lymphoma. The translocation leads to the overexpression of the C-MYC protein, which promotes unchecked cell proliferation and tumor growth. The C-MYC protein interacts with various transcription factors and proteins to regulate the cell cycle and apoptosis, ultimately contributing to the development of Burkitt lymphoma.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because C-MYC translocation is not typically associated with chronic lymphocytic leukemia (CLL). CLL is characterized by a different set of genetic abnormalities, including deletions and mutations in the TP53 gene.

**Option B:** This option is incorrect because while C-MYC is overexpressed in some cases of diffuse large B-cell lymphoma (DLBCL), it is not a specific hallmark of this disease. DLBCL is a heterogeneous group of lymphomas with various genetic abnormalities.

**Option C:** This option is incorrect because C-MYC translocation is not typically associated with follicular lymphoma. Follicular lymphoma is characterized by the translocation t(14;18), which involves the BCL2 gene.

**Clinical Pearl / High-Yield Fact**
C-MYC translocation is a specific genetic abnormality that is diagnostic of Burkitt lymphoma. It is essential to recognize this translocation in the context of lymphoma diagnosis, as it has significant implications for treatment and prognosis.

**Correct Answer: C. Burkitt lymphoma.**